

*Amendment and Response to Restriction Requirement*  
*U.S. Patent Application Serial No. 10/650,110*  
*Page 4*

RECEIVED  
CENTRAL FAX CENTER

OCT 20 2006

### REMARKS

The present application is directed to a method for treating Alzheimer disease in a patient. Prior to the present Response, Claims 1-16 were pending. Applicants cancel Claims 1-6 as non-elected and amend Claims 15-16 to correct unintentional typographical errors. The amendments do not introduce any new matter. Claims 7-16 will be pending upon entry of the amendments.

#### *Election/Restrictions*

In the Restriction Requirement mailed September 22, 2006, the Examiner requires applicants to elect, for examination purposes, one of the following two groups of claims.

I. Claims 1-6, drawn to a composition effective to prevent or delay the onset of Alzheimer's disease in a patient at risk of developing Alzheimer's disease comprising one or more partially delipidated protein particles, one or more partially delipidated lipoprotein particles or a combination thereof, classified in class 514, subclasses 2 or 558, depending on the agent used.

II. Claims 7-16, drawn to a method for treating Alzheimer's disease in a patient diagnosed with Alzheimer's disease comprising administration of an effective amount of one or more partially delipidated protein particles, one or more partially delipidated lipoprotein particles of a combination thereof, wherein the amount is effective to treat Alzheimer's disease in the patient, classified in class 514, subclasses 2 or 558, depending on the agent used.

The Examiner asserts that the two groups of claims are directed to two distinct inventions, a product and a process of use. Applicants elect Group II, Claims 7-16. Applicants cancel Claim 1-6 as non-elected.

*Amendment and Response to Restriction Requirement*  
*U.S. Patent Application Serial No. 10/650,110*  
*Page 5*

RECEIVED  
CENTRAL FAX CENTER


OCT 20 2006

### CONCLUSION

The foregoing is submitted as a full and complete response to the Restriction Requirement mailed September 22, 2006. No additional fees are believed due, however, the Commissioner is hereby authorized to charge any deficiencies which may be required or credit any overpayment to Deposit Account Number 11-0855.

Applicants assert that the claims are in condition for allowance and respectfully request that the application be passed to issuance. If the Examiner believes that any informalities remain in the case that may be corrected by Examiner's amendment, or that there are any other issues which can be resolved by a telephone interview, a telephone call to the undersigned agent at (404) 815-6102 or to Dr. John McDonald at (404) 745-2470 is respectfully solicited.

Respectfully submitted,



By: Elena S. Polovnikova, Ph.D.  
Patent Agent  
Reg. No.: 52,130

KILPATRICK STOCKTON LLP  
1100 Peachtree Street, Suite 2800  
Atlanta, GA 30309-4530  
Phone: (404) 815-6500  
Facsimile: (404) 815-6555  
Atty. Docket: 13131-0292 (44378-287574)